Inactive Instrument

Highlights Achillion Pharmaceuticals, Inc.

Equities

US00448Q2012

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Alexion Pharmaceuticals, Inc. completed the acquisition of Achillion Pharmaceuticals, Inc..	20-01-27	CI
Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting	19-12-09	CI
European Medicines Agency Grants Achillion PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor	19-11-19	CI
Achillion Pharmaceuticals, Inc. Announces Clearance of Investigational New Drug Application for ACH-5228	19-11-11	CI
Achillion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-07	CI
Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire Achillion Pharmaceuticals, Inc. for approximately $880 million.	19-10-15	CI
Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria	19-09-25	CI
Achillion Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-08	CI
Achillion Pharmaceuticals, Inc.'s ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers	19-07-22	CI
Achillion Pharmaceuticals, Inc. Announces the Final Data Set for ACH-4471 (Newly Designated “Danicopan”) Proof of Concept Phase 2 Trial in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria	19-06-10	CI
Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting	19-05-17	CI
Achillion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-09	CI
Achillion Pharmaceuticals Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy	19-04-03	CI
Achillion Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 PNH Combination Trial	19-03-27	CI
Achillion Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2018	19-03-07	CI
Achillion Pharmaceuticals, Inc. Announces Expansion into a Second Office in Blue Bell, Philadelphia	19-02-21	CI
Achillion Pharmaceuticals, Inc. Announces Dosing of the First Healthy Volunteer in A Phase 1 Multiple Ascending Dose Study of ACH-5228	19-01-31	CI
Achillion Pharmaceuticals, Inc. Reports Positive Interim Data for ACH-4471 Phase 2 Trials and Provides Clinical Development Strategy Update	18-12-17	CI
Mary Kay Fenton to Step Down as Chief Financial Officer of Achillion Pharmaceuticals, Inc, Effective Year End 2018	18-11-07	CI
Achillion Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	18-11-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Achillion Pharmaceuticals, Inc.

Equities

US00448Q2012

Highlights

Filters